FDA grants Glafabra an early meeting on Fabry gene therapy

By AI, Created 7:10 PM UTC, May 19, 2026, /AGP/ – The FDA has accepted Glafabra Therapeutics for an INTERACT meeting on July 16, 2026, giving the company early feedback on its lead Fabry disease gene therapy, GT-GLA-S03. The meeting could help shape an IND filing targeted for Q1 2027 and a planned Phase 1/2 trial.

Why it matters: - The FDA meeting gives Glafabra an early regulatory pathfinder for GT-GLA-S03, its lead Fabry disease program. - The INTERACT process can reduce uncertainty before a pre-IND or IND submission. - Glafabra is targeting an IND filing in Q1 2027 and first patient enrollment in Q3 2027. - GT-GLA-S03 is designed to replace lifelong enzyme replacement therapy with a single outpatient treatment.

What happened: - The FDA accepted Glafabra Therapeutics’ request for a face-to-face INTERACT meeting set for July 16, 2026. - The meeting will focus on GT-GLA-S03, a cell-based gene therapy for Fabry disease. - Glafabra said the meeting feedback will directly shape the IND submission. - The company described the acceptance as selective, noting that roughly 70% of INTERACT requests are declined, citing the BGTC Playbook (2025).

The details: - GT-GLA-S03 uses a patient’s own cells, modified with a lentivirus to produce the missing Fabry enzyme. - After reinfusion, the cells are intended to engraft in bone marrow and generate white blood cells that secrete the enzyme throughout the body. - The therapy is designed to enable cross-correction, where nearby cells absorb the enzyme and reduce toxic lipid buildup. - Current Fabry care relies on enzyme replacement therapy, or ERT, with 26 intravenous infusions a year for life. - Over five years, that adds up to 130 clinic visits. - Glafabra says GT-GLA-S03 is designed to deliver at least five years of benefit through one outpatient procedure. - The program has FDA Orphan Drug Designation. - Five-year data from the FACTS trial (NCT02800070) forms the clinical base for the program. - The investigator-initiated FACTS study was led in Canada by Glafabra co-founders Dr. Jeffrey Medin and Dr. Ronan Foley. - Five patients followed for five years showed zero product-attributable serious adverse events. - Plasma lyso-Gb3 fell 48% from the no-ERT baseline, with p<0.0001 and 99% statistical power. - Four of five patients kept lyso-Gb3 below the elevated threshold at five years. - Four of five patients received conditioning as a same-day outpatient procedure. - The results have been published in Nature Communications and Clinical and Translational Medicine.

Between the lines: - Glafabra is positioning GT-GLA-S03 as a broader solution than existing Fabry options. - The company says chaperone-based therapies reach only 40% of patients. - Roughly 30% of ERT-treated patients develop neutralizing antibodies that can blunt treatment. - In FACTS, pre-existing antibody responses diminished over time in patients treated with GT-GLA-S03. - AAV-based gene therapies face another hurdle because pre-existing anti-capsid antibodies exclude roughly one-third of patients. - Glafabra says GT-GLA-S03 has no such barrier and could be repeatable, variant-agnostic and antibody-status-agnostic. - The company also sees potential for the therapy as rescue treatment after failed AAV trials. - The outpatient conditioning uses low-dose melphalan and is described as less burdensome than busulfan-based regimens. - Glafabra is also framing the Live-cel platform as a broader business, not a single-product bet. - GT-GAA-S04 for Pompe disease and GT-GBA1-S05 for Gaucher disease are both preclinical. - Those programs could qualify for Orphan Drug and Rare Pediatric Disease Designation. - Recent Priority Review Voucher transactions cited by Glafabra include Zevra, Acadia and PTC at $150 million, Abeona at $155 million and Ipsen at $158 million. - The Rare Pediatric Disease PRV program was reauthorized in February 2026 through September 2029 under the Consolidated Appropriations Act. - Glafabra says the Live-cel platform could extend to about 70 lysosomal storage disorders and 900 known enzyme deficiency disorders.

What’s next: - Glafabra plans to use the INTERACT feedback to prepare its IND filing. - The company is targeting first patient enrollment in Q3 2027 at University of Utah Health. - Additional development of the Live-cel platform will continue across lysosomal storage disorder programs.

The bottom line: - The FDA meeting is a meaningful de-risking step for Glafabra’s Fabry program and a key checkpoint before the company seeks formal trial clearance.